PharmaLex Expands Nordic Presence, Merges with DRA Consulting
Partnership adds technological offerings to PharmaLex’s repertoire
PharmaLex Group, a specialized services source for the pharma, biotech, and medtech industries, has announced a merger with Finnish consulting company, DRA Consulting. The consulting firm will become part of the broader PharmaLex Nordic region after the merger, making the Nordics the fourth largest market for PharmaLex.
The merger adds several state-of-the-art technology solutions to PharmaLex’s growing digital platform, including robotics capabilities for pharmacovigilance, automation for writing sections of the CMC, and tools to harmonize some regulatory tasks.
“The merger is integral to helping us remain competitive in the future and to increasing our global market share. Together, with PharmaLex, we can achieve a stronger presence in the Nordic countries and globally giving our clients access to broader expertise in multiple markets,” notes Kaija Korpiaho-Haga, CEO, partner, and co-founder of DRA Consulting.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
